索拉非尼与舒尼替尼单药治疗对HCC患者症状改善程度及副作用的影响  

Effects of solafenib and Sunitinib monotherapy on symptom improvement and side effects in HCC patients

作　　者：刘永辉 曹俊东[2] LIU Yonghui;CAO Jundong(The Third Affiliated Hospital of Kunming Medical University,Yunnan Cancer Hospital,Kunming 650118,China;Affiliated Hospital of Kunming University of Science and Technology,The First People’s Hospital of Yunnan Province,Kunming 650032,China)

机构地区：[1]云南省肿瘤医院昆明医科大学第三附属医院,云南昆明650118 [2]云南省第一人民医院昆明理工大学附属医院,云南昆明650032

出　　处：《当代医药论丛》2023年第18期105-108,共4页

摘　　要：目的:分析索拉非尼与舒尼替尼单药治疗对肝细胞癌(HepatoceUular Carcinoma,HCC)患者症状改善程度及副作用的影响。方法:本研究纳入云南省肿瘤医院昆明医科大学第三附属医院近2年(2021年1月至2022年12月)收治的HCC患者60例作为研究对象,随机分为观察组(30例)、对照组(30例)。观察组采用索拉非尼治疗,对照组采用舒尼替尼治疗,两组HCC患者持续治疗半年后统计分析其疗效状况和不良反应发生情况。结果:观察组HCC患者的总有效率(80.00%)显著高于对照组HCC患者(53.33%),差异具有统计学意义(P<0.05);观察组HCC患者在本次药物治疗期间出现了10例药物相关不良反应,不良反应发生率33.33%,虽然略低于对照组的40.00%,但组间差异无统计学意义(P>0.05)。结论:索拉非尼单药改善HCC患者症状的效果显著优于舒尼替尼,且不会明显增加副作用。Objective:To analyze the effects of sorafenib and Sunitinib on the improvement of symptoms and side effects of HepatoceUular Carcinoma(HCC).Methods:In this study,60 HCC patients admitted to the Third Affiliated Hospital of Kunming Medical University,Yunnan Cancer Hospital in the past 2 years(January 2021 to December 2022)were enrolled as research objects,and randomly divided into observation group(30 cases)and control group(30 cases).The observation group was treated with sorafenib,while the control group was treated with sunitinib.The efficacy and adverse reactions of HCC patients in both groups were statistically analyzed after continuous treatment for half a year.Results:The total effective rate of HCC patients in observation group(80.00%)was significantly higher than that in control group(53.33%),the difference was statistically significant(P<0.05).There were 10 cases of drug-related adverse reactions in HCC patients in the observation group during this drug treatment,and the incidence of adverse reactions was 33.33%,which was slightly lower than 40.00% in the control group,but there was no statistical significance between groups(P>0.05).Conclusion:Sorafenib alone is significantly better than Sunitinib in improving the symptoms of HCC patients,and does not significantly increase side effects.

关 键 词：索拉非尼 舒尼替尼 HCC 副作用 

分 类 号：R73[医药卫生—肿瘤]